Skip to content

Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial

This trial, designed to study the dosage Mebendazole should be administered, saw 17 patients reach the maximum dose administered with no toxicity.

Those patients that reached and sustained Mebendazole use for more than one month experienced greater progression-free survival and lived longer than those in the control group.

At the time of publication, 6 years after the trial began, there were 2 patients alive and still taking Mebendazole.

Share on facebook
Share on email
Share on twitter
Share on linkedin

More on Mebendazole

Notify of
Inline Feedbacks
View all comments